We selected the RL/+ mutants for this in vivo drug screen as these mutants do not exhibit the high rate of premature death observed in other SCN8A epilepsy mouse models (Wagnon et al., 2015; Bunton-Stasyshyn et al., 2019). Here, SCN8A is linked to epilepsy.